Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea
Jun Ho Yi1, Gyeong-Won Lee2, Ji Hyun Lee3, Kwai Han Yoo4, Chul Won Jung5, Dae Sik Kim6, Jeong-Ok Lee7, Hyeon Seok Eom8, Ja Min Byun9, Youngil Koh9, Sung Soo Yoon9, Jin Seok Kim10, Jee Hyun Kong11, Ho-Young Yhim12, Deok-Hwan Yang13, Dok Hyun Yoon14, Do Hyoung Lim15, Won-Sik Lee16, Ho-Jin Shin17
Division of Hematology-Oncology, 1Department of Medicine, Chung-Ang University Hospital, Seoul, 2Gyeongsang National University College of Medicine, Jinju, 3Department of Internal Medicine, Dong-A University College of Medicine, Pusan, 4Gachon University College of Medicine, Incheon, 5Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Internal Medicine, 6Korea University Guro Hospital, Seoul, 7Seoul National University Bundang Hospital, Seongnam, 8National Cancer Center, Goyang, 9Seoul National University Hospital, 10Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, 11Division of Hematology-Oncology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, 12Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, 13Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Gwangju, 14Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Division of Hematology-Oncology, Department of Internal Medicine, 15Dankook University College of Medicine, Cheonan, 16Inje University Busan Paik Hospital, 17School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Korea
Correspondence to: Ho-Jin Shin M.D., Ph.D.
Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, 179 Gudeok-ro, Seo-gu, Busan 49241, Korea
E-mail: hojinja@hanmail.net
Published online: November 22, 2021.
© The Korean Journal of Hematology. All rights reserved.

Abstract
Background: Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western countries but is rare in the East Asian countries. Due to its rarity and the lack of feasible novel agents and laboratory prognostic tools, there are limited data on the clinical outcomes of this disease in Asia. To clarify the current treatment status, we performed a multicenter retrospective analysis of patients with CLL in Korea.
Methods: The medical records of 192 eligible patients between 2008 and 2019 were reviewed for clinical characteristics, treatment courses, and outcomes. The first-line treatment regimens of the patients included in this analysis were as follows: fludarabine/cyclophosphamide/rituximab (FCR) (N=117, 52.7%), obinutuzumab plus chlorambucil (GC) (N=30, 13.5%), and chlorambucil monotherapy (N=24, 10.8%).
Results: The median progression-free survival (PFS) was 55.6 months, and the average 2-year PFS rate was 80.3%. PFS was not significantly different between the patients receiving FCR and those receiving GC; however, chlorambucil treatment was associated with significantly inferior PFS (P<0.001). The median overall survival was 136.3 months, and the average 5- and 10-year OS rates were 82.0% and 57.4%, respectively.
Conclusions: This is one of the largest studies involving Korean patients with CLL. Although the patients had been treated with less favored treatment regimens, the outcomes were not different from those reported in Western studies.
Keywords: Chronic lymphocytic leukemia, Outcomes, Asia


e-submission

This Article

Current Issue

ba_link01

SCImago Journal & Country Rank

Indexed/Covered by

Today : 23  /
Total : 368,349